1例2型糖尿病伴骨质疏松患者的药学监护
投稿时间:2021-10-12  修订日期:2022-01-21  点此下载全文
引用本文:骆锦前,陆松伟,田泾,虞慧华.1例2型糖尿病伴骨质疏松患者的药学监护[J].药学实践杂志,2022,40(5):473~476
摘要点击次数: 110
全文下载次数: 132
作者单位E-mail
骆锦前 海军军医大学第一附属医院药学部, 上海 200433  
陆松伟 海军军医大学第一附属医院药学部, 上海 200433 chinalsw2000@sina.com 
田泾 海军军医大学第一附属医院药学部, 上海 200433  
虞慧华 海军军医大学第一附属医院药学部, 上海 200433  
中文摘要:目的 探讨糖尿病合并骨质疏松患者的疾病特点及药学监护要点,为临床合理有效用药提供参考。方法 临床药师通过参与1例2型糖尿病伴骨质疏松患者的用药分析,结合患者疾病特点及病理特征,并提出药学建议,协助治疗方案的优化。结果 治疗方案重整及药学监护后,患者的治疗效果得到明显改善。结论 糖尿病性骨质疏松发病机制复杂,当前的治疗以降血糖联合抗骨质疏松药物为主,通过慢病用药管理、药学监护,可以促进合理用药。
中文关键词:糖尿病  骨质疏松  糖尿病性骨质疏松  慢病用药管理  药学监护
 
Pharmaceutical care of a patient with type 2 diabetes and osteoporosis
Abstract:Objective To investigate the disease characteristics and key factors of pharmaceutical care in patients with diabetes and osteoporosis, and provide references for clinical rational and effective medication. Methods Clinical pharmacist participated in the drug analysis of a patient with type 2 diabetes and osteoporosis. The pharmaceutical recommendations were proposed to assist physicians in optimizing the treatment plan, combined with the patient’s disease characteristics and pathological characteristics. Results After the reorganization of the treatment plan and pharmaceutical care, the patient's treatment effect had been significantly improved. Conclusion The pathogenesis of diabetic osteoporosis is complex. The current treatment is based on hypoglycemic combined with anti-osteoporosis drugs. Through chronic disease drug management and pharmaceutical monitoring, rational drug use could be promoted.
keywords:diabetes  osteoporosis  diabetic osteoporosis  chronic disease medication management  pharmaceutical care
查看全文  查看/发表评论  下载PDF阅读器
关闭

分享按钮